Reaction
Nasal Mucosal Disorder reporting signals
As of the last recalculation, Nasal Mucosal Disorder appears in 577 FAERS reports alongside 25 co-occurring drug terms. The strongest observed disproportionality signal is ADO-TRASTUZUMAB EMTANSINE (PRR 174.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ado-Trastuzumab Emtansine | 38 | 174.0 | 174.8 |
| Carboxymethylcellulose Sodium | 36 | 147.3 | 147.9 |
| Dronabinol | 29 | 136.9 | 137.4 |
| Bleomycin Sulfate | 35 | 130.0 | 130.5 |
| Lapatinib | 38 | 94.5 | 94.7 |
| Fam-Trastuzumab Deruxtecan-Nxki | 25 | 93.5 | 93.7 |
| Ciclesonide | 30 | 83.8 | 83.9 |
| Fosaprepitant Dimeglumine | 27 | 74.3 | 74.4 |
| Aprepitant | 28 | 57.4 | 57.5 |
| Fulvestrant | 47 | 55.8 | 55.9 |
| Pertuzumab | 39 | 55.4 | 55.5 |
| Trazodone Hydrochloride | 22 | 52.7 | 52.8 |
| Lactulose | 40 | 40.4 | 40.4 |
| Doxorubicin Hydrochloride | 33 | 38.6 | 38.6 |
| Cefepime Hydrochloride | 14 | 32.1 | 32.1 |
| Trimethoprim | 10 | 31.1 | 31.1 |
| Cefepime | 11 | 28.2 | 28.2 |
| Indapamide | 13 | 26.7 | 26.8 |
| Amphotericin B | 9 | 26.3 | 26.3 |
| Trastuzumab | 43 | 24.3 | 24.4 |
| Alpelisib | 5 | 20.9 | 20.9 |
| Capecitabine | 46 | 19.6 | 19.6 |
| Docetaxel Anhydrous | 26 | 14.5 | 14.5 |
| Docetaxel | 26 | 14.5 | 14.5 |
| Pegfilgrastim | 24 | 9.1 | 9.1 |